Osborne Clarke in Amsterdam has advised iOnctura, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, in raising an additional EUR 5.1 million bringing the total Series A financing to EUR 20.1 million.
New investors 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR joins the existing blue chip investor syndicate of M Ventures, INKEF Capital, VI Partners, and Schroder Adveq, which all participated in the extension.
The Osborne Clarke in Amsterdam team consisted of Partner Herke van Hulst, Senior Associate Geoffrey Beurskens and Associate Florien Sanders (Corporate M&A), and Partners Cars-Jan van Gool (Civil Law Notary) and Associate Arlette Vrolijk (Candidate Civil-Law Notary).
Osborne Clarke’s international life science and healthcare sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market. Recent notable work from the team in Amsterdam includes advising the syndicate of investors in the EUR 32 million Series B financing round of VarmX.